Federal Circuit Hears Appeal Over Acadia's Nuplazid Formulation Patent

• The U.S. Federal Circuit heard oral arguments in Acadia Pharmaceuticals’ appeal involving patent protection for the Nuplazid 34 mg capsule formulation.
• The appeal challenges a Delaware federal court’s May 2025 decision upholding U.S. Patent No. 11,452,721.
• Acadia expects a ruling in the first half of 2027, though the court has no set deadline.
• If upheld, the formulation patent is expected to protect the Nuplazid 34 mg capsule until February 2038.
• If overturned, protection is expected through October 2030 under the previously upheld pimavanserin composition-of-matter patent and associated pediatric exclusivity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611092347BIZWIRE_USPR_____20261109_BW799468) on November 10, 2026, and is solely responsible for the information contained therein.